Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2009 2
2011 3
2014 1
2015 1
2017 4
2018 3
2019 5
2020 6
2021 5
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
TACkling Cancer by Targeting Selective Protein Degradation.
Noblejas-López MDM, Tébar-García D, López-Rosa R, Alcaraz-Sanabria A, Cristóbal-Cueto P, Pinedo-Serrano A, Rivas-García L, Galán-Moya EM. Noblejas-López MDM, et al. Among authors: galan moya em. Pharmaceutics. 2023 Oct 10;15(10):2442. doi: 10.3390/pharmaceutics15102442. Pharmaceutics. 2023. PMID: 37896202 Free PMC article. Review.
PAKing up to the endothelium.
Galan Moya EM, Le Guelte A, Gavard J. Galan Moya EM, et al. Cell Signal. 2009 Dec;21(12):1727-37. doi: 10.1016/j.cellsig.2009.08.006. Epub 2009 Aug 29. Cell Signal. 2009. PMID: 19720142 Free article. Review.
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.
Noblejas-López MDM, Gandullo-Sánchez L, Galán-Moya EM, López-Rosa R, Tébar-García D, Nieto-Jiménez C, Gómez-Juárez M, Burgos M, Pandiella A, Ocaña A. Noblejas-López MDM, et al. Among authors: galan moya em. Int J Mol Sci. 2022 May 13;23(10):5476. doi: 10.3390/ijms23105476. Int J Mol Sci. 2022. PMID: 35628286 Free PMC article.
Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis.
Burgos M, Cavero-Redondo I, Álvarez-Bueno C, Galán-Moya EM, Pandiella A, Amir E, Ocaña A. Burgos M, et al. Ther Adv Med Oncol. 2022 Jan 19;14:17588359211072621. doi: 10.1177/17588359211072621. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35082925 Free PMC article.
MZ1 co-operates with trastuzumab in HER2 positive breast cancer.
Noblejas-López MDM, Nieto-Jiménez C, Galán-Moya EM, Tebar-García D, Montero JC, Pandiella A, Burgos M, Ocaña A. Noblejas-López MDM, et al. Among authors: galan moya em. J Exp Clin Cancer Res. 2021 Mar 19;40(1):106. doi: 10.1186/s13046-021-01907-9. J Exp Clin Cancer Res. 2021. PMID: 33741018 Free PMC article.
Genomic Correlates of DNA Damage in Breast Cancer Subtypes.
Cabañas Morafraile E, Pérez-Peña J, Fuentes-Antrás J, Manzano A, Pérez-Segura P, Pandiella A, Galán-Moya EM, Ocaña A. Cabañas Morafraile E, et al. Among authors: galan moya em. Cancers (Basel). 2021 Apr 27;13(9):2117. doi: 10.3390/cancers13092117. Cancers (Basel). 2021. PMID: 33925616 Free PMC article.
37 results